SynAct Pharma AB

Stocks

SYNACT

SE0008241491

Market Closed - Nasdaq Stockholm Other stock markets 19:00:00 22/06/2026 +03			5-day change	1st Jan Change
14.90 ^SEK	+27.79%		+23.14%	-34.07%

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
06-18	Synact Pharma no longer has any publicly disclosed short seller	FW

Transcript : SynAct Pharma AB - Special Call

Published on 06/15/2026 at 07:51 pm +03

S&P Capital IQ

Presenter Speech
Unknown Attendee (Attendees)

Here at Investor Studios, we are joined by SynAct Pharma, who today have announced the top line results for the Phase IIb ADVANCE study. And joining me

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about SynAct Pharma AB

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
06-18	Synact Pharma no longer has any publicly disclosed short seller	FW
06-17	Citadel Securities Europe emerges as new short seller in Synact Pharma	FW
06-15	SynAct Pharma AB - Special Call
06-15	Peace Agreement Bolsters Stockholm Exchange, OMXS30 Index Gains 0.7 Percent	FW
06-15	Commodities and Industrials Show Strength on Stockholm Exchange, OMXS30 Index Gains 1.4 Percent	FW
06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-15	Stockholm Stock Exchange surges at the open, OMXS30 index gains 2.0 percent	FW
06-15	Synact Pharma Board and Management Enter Into Lock-Up Agreements	FW
06-15	Synact Pharma's resomelagon misses primary endpoint (Update)	FW
06-15	Synact Pharma reports positive Phase 2 results for rheumatoid arthritis treatment	FW
06-15	SynAct Pharma AB Reports Positive Results from Phase 2B Advance Study of Resomelagon in Rheumatoid Arthritis	CI
06-12	Peace Optimism Lifts Stockholm Exchange: Duni Falls on Profit Warning	FW
06-12	Synact secures US patent for resomelagon: exclusivity extended to 2044	FW
06-12	Synact Pharma Secures U.S. Patent	FW